179 lines
52 KiB
Text
179 lines
52 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK23602">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK23602/?report=reader">
|
|
<meta name="ncbi_pagename" content="111In-DOTA-Re(Cys3,4,10,d-Phe7,Arg11)αMSH3-13 - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>111In-DOTA-Re(Cys3,4,10,d-Phe7,Arg11)αMSH3-13 - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/RM1-DOTA-111In/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/DPC11870In111/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="111In-DOTA-Re(Cys3,4,10,d-Phe7,Arg11)αMSH3-13">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2007/12/17">
|
|
<meta name="citation_author" content="Kenneth T. Cheng">
|
|
<meta name="citation_author" content="Zhen Cheng">
|
|
<meta name="citation_author" content="Thomas P. Quinn">
|
|
<meta name="citation_pmid" content="20641798">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK23602/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="111In-DOTA-Re(Cys3,4,10,d-Phe7,Arg11)αMSH3-13">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Kenneth T. Cheng">
|
|
<meta name="DC.Contributor" content="Zhen Cheng">
|
|
<meta name="DC.Contributor" content="Thomas P. Quinn">
|
|
<meta name="DC.Date" content="2007/12/17">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK23602/">
|
|
<meta name="description" content="111In-DOTA-[Cys3,4,10,d-Phe7,Arg11]αMSH3-13 (111In-DOTA-Re(Arg11)CCMSH) is a radioligand developed as an imaging probe for single-photon emission computed tomography (SPECT) of primary and metastatic melanoma (1, 2). 111In is a gamma emitter with a physical half-life (t½) of 2.8 days.">
|
|
<meta name="og:title" content="111In-DOTA-Re(Cys3,4,10,d-Phe7,Arg11)αMSH3-13">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="111In-DOTA-[Cys3,4,10,d-Phe7,Arg11]αMSH3-13 (111In-DOTA-Re(Arg11)CCMSH) is a radioligand developed as an imaging probe for single-photon emission computed tomography (SPECT) of primary and metastatic melanoma (1, 2). 111In is a gamma emitter with a physical half-life (t½) of 2.8 days.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK23602/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/CCMSH111In/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK23602/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8DC3D27D64DB810000000000050005.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK23602/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/RM1-DOTA-111In/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">111In-DOTA-Re(Cys3,4,10,d-Phe7,Arg11)αMSH3-13</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/DPC11870In111/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK23602/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK23602/&text=111In-DOTA-Re(Cys3%2C4%2C10%2Cd-Phe7%2CArg11)%003B1MSH3-13"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK23602/?report=classic">Switch to classic view</a><a href="/books/NBK23602/pdf/Bookshelf_NBK23602.pdf">PDF (407K)</a><a href="/books/NBK23602/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK23602%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8DC3D27D64DB810000000000050005.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK23602_"><span class="title" itemprop="name"><sup>111</sup>In-DOTA-Re(Cys<sup>3,4,10</sup>,<span class="small-caps">d</span>-Phe<sup>7</sup>,Arg<sup>11</sup>)αMSH<sub>3-13</sub></span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm"><sup>111</sup>In-DOTA-Re(Arg<sup>11</sup>)CCMSH</div><p class="contribs">Cheng KT, Cheng Z, Quinn TP.</p><p class="fm-aai"><a href="#_NBK23602_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCCMSH111InT1"><a href="/books/NBK23602/table/CCMSH111In.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobCCMSH111InT1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="CCMSH111In.T1"><a href="/books/NBK23602/table/CCMSH111In.T1/?report=objectonly" target="object" rid-ob="figobCCMSH111InT1">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Rodents
|
|
</p></div></div><div id="CCMSH111In.Background"><h2 id="_CCMSH111In_Background_">Background</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%2899mTc-%20and%20111In-labeled%20alpha-melanocyte-stimulating%20hormone%20peptides%29%20OR%20%28radiolabeled-alpha-MSH%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p><sup>111</sup>In-DOTA-[Cys<sup>3,4,10</sup>,<span class="small-caps">d</span>-Phe<sup>7</sup>,Arg<sup>11</sup>]αMSH<sub>3-13</sub> (<sup>111</sup>In-DOTA-Re(Arg<sup>11</sup>)CCMSH) is a radioligand developed as an imaging probe for single-photon emission computed tomography (SPECT) of primary and metastatic melanoma (<a class="bibr" href="#CCMSH111In.EXTYLES.1" rid="CCMSH111In.EXTYLES.1">1</a>, <a class="bibr" href="#CCMSH111In.EXTYLES.2" rid="CCMSH111In.EXTYLES.2">2</a>). <sup>111</sup>In is a gamma emitter with a physical half-life (<i>t</i><sub>½</sub>) of 2.8 days.</p><p>Malignant melanoma is the sixth most common cancer in the United States (<a class="bibr" href="#CCMSH111In.EXTYLES.2" rid="CCMSH111In.EXTYLES.2">2</a>). Early diagnosis and prompt surgical removal is the best approach for treatment (<a class="bibr" href="#CCMSH111In.EXTYLES.2" rid="CCMSH111In.EXTYLES.2">2</a>, <a class="bibr" href="#CCMSH111In.EXTYLES.3" rid="CCMSH111In.EXTYLES.3">3</a>). The melanocortin (MC) system is the best characterized neuropeptide network of the skin, and it is involved in pigmentation regulation, cortisol production, and many other physiological processes (<a class="bibr" href="#CCMSH111In.EXTYLES.4" rid="CCMSH111In.EXTYLES.4">4</a>). Most cutaneous cell types express MC receptors, proopiomelanocortin (POMC), and prohormone convertases, and they also release MCs. Five MC receptors (MC-1 to MC-5) have been cloned and characterized as receptors that belong to the G-protein–coupled receptor superfamily. The melanocyte-stimulating hormones (MSHs) α-, β-, and γ-MSH are derived from POMC by the proteolytic action of prohormone convertases. α-MSH (Ac-Ser<sup>1</sup>-Tyr<sup>2</sup>-Ser<sup>3</sup>-Met<sup>4</sup>-Glu<sup>5</sup>-His<sup>6</sup>-Phe<sup>7</sup>-Arg<sup>8</sup>-Trp<sup>9</sup>-Gly<sup>10</sup>-Lys<sup>11</sup>-Pro<sup>12</sup>-Val<sup>13</sup>-NH<sub>2</sub>), composed of 13 amino acids, is the most potent naturally occurring melanotropic peptide (<a class="bibr" href="#CCMSH111In.EXTYLES.5" rid="CCMSH111In.EXTYLES.5">5</a>). The biologic effects of α-MSH are mediated <i>via</i> MC receptors.</p><p>Although positron emission tomography imaging with [<sup>18</sup>F]fluoro-2-deoxy-2-<span class="small-caps">d</span>-glucose ([<sup>18</sup>F]FDG) is effective in the detection of melanoma, it is not melanoma-specific and some melanoma cells do not take up [<sup>18</sup>F]FDG (<a class="bibr" href="#CCMSH111In.EXTYLES.6" rid="CCMSH111In.EXTYLES.6">6</a>, <a class="bibr" href="#CCMSH111In.EXTYLES.7" rid="CCMSH111In.EXTYLES.7">7</a>). Radiolabeled α-MSH peptide analogs have been shown to specifically bind to MC-1 receptors that are overexpressed on human and mouse melanoma cells (<a href="#CCMSH111In.EXTYLES.8">8-11</a>). Giblin et al. (<a class="bibr" href="#CCMSH111In.EXTYLES.12" rid="CCMSH111In.EXTYLES.12">12</a>) used metal cyclization to design a new class of α-MSH peptide analogs that are resistant to chemical and proteolytic degradation <i>in vivo</i>. α-MSH analogs were cyclized through site-specific rhenium (Re) metal coordination to form Re[(Cys<sup>3,4,10</sup>,<span class="small-caps">d</span>-Phe<sup>7</sup>)αMSH<sub>3-13</sub> (ReCCMSH). ReCCMSH displayed a receptor-binding affinity of 2.9 nM, 25-fold higher than the Re-CMSH analog. Additional studies have reported successful use of 1,4,7,10-tetraazacyclodecane-<i>N</i>,<i>N'</i>,<i>N''</i>,<i>N'''</i>-tetraacetic acid (DOTA) coupled to the cyclic ReCCMSH peptide analogs (<a class="bibr" href="#CCMSH111In.EXTYLES.1" rid="CCMSH111In.EXTYLES.1">1</a>, <a class="bibr" href="#CCMSH111In.EXTYLES.13" rid="CCMSH111In.EXTYLES.13">13</a>) and linear α-MSH analogs (<a href="#CCMSH111In.EXTYLES.14">14-16</a>) for radiolabeling. These α-MSH derivatives (DOTA-α-MSH) were labeled with a variety of radionuclides (<a class="bibr" href="#CCMSH111In.EXTYLES.3" rid="CCMSH111In.EXTYLES.3">3</a>, <a class="bibr" href="#CCMSH111In.EXTYLES.12" rid="CCMSH111In.EXTYLES.12">12</a>, <a class="bibr" href="#CCMSH111In.EXTYLES.13" rid="CCMSH111In.EXTYLES.13">13</a>, <a href="#CCMSH111In.EXTYLES.16">16-19</a>). Cheng et al. (<a class="bibr" href="#CCMSH111In.EXTYLES.1" rid="CCMSH111In.EXTYLES.1">1</a>) showed that the kidney uptake of a rhenium cyclized DOTA-α-MSH analog [DOTA-Re(Arg<sup>11</sup>)CCMSH] could be considerably reduced and tumor uptake could be enhanced significantly by substitution the Lys<sup>11</sup> residue with Arg<sup>11</sup> in order to delocalize the charge of the Lys<sup>11</sup> residue. <sup>111</sup>In-DOTA-Re(Arg<sup>11</sup>)CCMSH showed favorable tumor imaging properties in mice bearing murine melanoma (<a class="bibr" href="#CCMSH111In.EXTYLES.2" rid="CCMSH111In.EXTYLES.2">2</a>). Miao et al. (<a class="bibr" href="#CCMSH111In.EXTYLES.11" rid="CCMSH111In.EXTYLES.11">11</a>) also replaced the Lys<sup>11</sup> with Arg<sup>11</sup> in the ReCCMSH analog to form Re(Arg<sup>11</sup>)CCMSH in an effort to reduce nonspecific kidney uptake and minimize the kidney radiation dose. Linear MSH analogs, conjugated with DOTA, also demonstrated melanoma tumor targeting. Chen et al. (<a class="bibr" href="#CCMSH111In.EXTYLES.14" rid="CCMSH111In.EXTYLES.14">14</a>) demonstrated moderate tumor uptake of the MSH analog <sup>111</sup>In-DOTA-NDP. Eberle and Froidevaux (<a class="bibr" href="#CCMSH111In.EXTYLES.15" rid="CCMSH111In.EXTYLES.15">15</a>) prepared a minimal α-MSH analog <sup>111</sup>In-DOTA-MSH<sub>OCT</sub> that showed good <i>in vitro</i> and <i>in vivo</i> targeting properties. Froidevaux et al. (<a class="bibr" href="#CCMSH111In.EXTYLES.16" rid="CCMSH111In.EXTYLES.16">16</a>) changed the location of DOTA conjugation to Lys<sup>11</sup> yielding DOTA-NAPamide with reduced kidney uptake by neutralizing the charge of the Lys residue. While these linear DOTA-MSH analogs exhibited tumor uptake and rapid clearance, they did not achieve the percent dose per gram and retention time of the cyclic DOTA-MSH peptides.</p></div><div id="CCMSH111In.Synthesis"><h2 id="_CCMSH111In_Synthesis_">Synthesis</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%2899mTc-%20and%20111In-labeled%20alpha-melanocyte-stimulating%20hormone%20peptides%29%20OR%20%28radiolabeled-alpha-MSH%29%20AND%20synthesis" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Cheng et al (<a class="bibr" href="#CCMSH111In.EXTYLES.1" rid="CCMSH111In.EXTYLES.1">1</a>) and Miao et al. (<a class="bibr" href="#CCMSH111In.EXTYLES.17" rid="CCMSH111In.EXTYLES.17">17</a>) reported the synthesis of the DOTA-(Arg<sup>11</sup>)CCMSH using the standard fluorenylmethoxycarbonyl (Fmoc)/HBTU chemistry on amide resin. A solid-phase peptide synthesizer was used. DOTA-tri-<i>t</i>-butyl ester was coupled to the <i>N</i>-terminus of the peptide during the terminal round of synthesis. The peptide was deprotected and cleaved from the resin by a mixture of trifluoroacetic acid, thioanisol, ethanedithiol, and water at room temperature for 3 h. DOTA-Re(Arg<sup>11</sup>)CCMSH was cyclized by site-specific Re coordination. DOTA-Re(Arg<sup>11</sup>)CCMSH and ReOCl<sub>3</sub>(Me<sub>2</sub>S)(OPPh<sub>3</sub>) were dissolved in 60% methanol aqueous solution (1:1.5 molar ratio). The pH was adjusted to ~8, and the mixture was incubated at 70ºC for 1 h. DOTA-Re(Arg<sup>11</sup>)CCMSH was collected by centrifugation and purified by high-performance liquid chromatography (HPLC) (<a class="bibr" href="#CCMSH111In.EXTYLES.13" rid="CCMSH111In.EXTYLES.13">13</a>). Radiolabeling with <sup>111</sup>In was performed by mixing <sup>111</sup>In-chloride in ammonium acetate with 10 μg peptide and incubating at 70ºC for 45 min. <sup>111</sup>In-DOTA-(Arg<sup>11</sup>)CCMSH was purified by HPLC. The specific activity was reported to be 8.1164 × 10<sup>8</sup> MBq/g (2.1936 × 10<sup>7</sup> mCi/g). On the basis of the peptide molecular weight of ~1990, the specific activity was ~1.6152 × 10<sup>10</sup> MBq/μmol (4.3654 × 10<sup>8</sup> mCi/ μmol).</p></div><div id="CCMSH111In.In_Vitro_Studies_Tes"><h2 id="_CCMSH111In_In_Vitro_Studies_Tes_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28%2899mTc-%20and%20111In-labeled%20alpha-melanocyte-stimulating%20hormone%20peptides%29%20OR%20%28radiolabeled-alpha-MSH%29%29%20AND%20in%20vitro" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Cheng et al. (<a class="bibr" href="#CCMSH111In.EXTYLES.1" rid="CCMSH111In.EXTYLES.1">1</a>) performed <i>in vitro</i> quantitative receptor-binding assays of unlabeled CCMSH on B16/F1 murine melanoma cells. The inhibition constant (<i>K</i><sub>i</sub>) was determined to be 7.6 × 10−<sup>9</sup> M. Chen et al. (<a class="bibr" href="#CCMSH111In.EXTYLES.13" rid="CCMSH111In.EXTYLES.13">13</a>) determined the 50% inhibiton concentration IC<sub>50</sub> of unlabeled DOTA-ReCCMSH to be 1.2 ± 0.3 nmol/liter. In comparison, the IC<sub>50</sub> of unlabeled ReCCMSH was 2.9 ± 0.3 nmol/liter (<a class="bibr" href="#CCMSH111In.EXTYLES.12" rid="CCMSH111In.EXTYLES.12">12</a>).</p></div><div id="CCMSH111In.Animal_Studies"><h2 id="_CCMSH111In_Animal_Studies_">Animal Studies</h2><div id="CCMSH111In.Rodents"><h3>Rodents</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28%2899mTc-%20and%20111In-labeled%20alpha-melanocyte-stimulating%20hormone%20peptides%29%20OR%20%28radiolabeled-alpha-MSH%29%29%20AND%20rodentia" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Biodistribution and SPECT imaging studies with <sup>111</sup>In-DOTA-Re(Arg<sup>11</sup>)CCMSH were conducted in C57 mice bearing B16/F1 (flank melanoma tumors) (<a class="bibr" href="#CCMSH111In.EXTYLES.1" rid="CCMSH111In.EXTYLES.1">1</a>, <a class="bibr" href="#CCMSH111In.EXTYLES.2" rid="CCMSH111In.EXTYLES.2">2</a>) and B16/F10 (pulmonary metastatic melanoma tumors) tumors (<a class="bibr" href="#CCMSH111In.EXTYLES.2" rid="CCMSH111In.EXTYLES.2">2</a>). Each mouse received 20.35 MBq (0.55 mCi) of <sup>111</sup>In-DOTA-Re(Arg<sup>11</sup>)CCMSH by intravenous administration. The radioactivity levels as percentage injected dose per g (% ID/g) in the flank tumors (<i>n</i> = 4) were 17.29 ± 2.49 (2 h), 17.41 ± 5.63 (4 h), and 8.19 ± 1.63 (24 h). The tumor/muscle ratios were 576.33 (2 h), 193.44 (4 h), and 58.50 (24 h). The critical organ appeared to be the kidneys with 8.72 ± 1.34 (2 h), 7.73 ± 1.13 (4 h), and 5.64 ± 0.52 (24 h). The tumor/kidney ratios were 1.98 (2 h), 2.36 (4 h), and 1.45 (24 h). Approximately 90% ID/g was cleared from the body in 4 h. The other major organ radioactivity levels (% ID/g) at 2 h were 0.40 ± 0.04 (intestines), 0.23 ± 0.05 (stomach), 0.38 ± 0.04 (liver), 0.30 ± 0.09 (lung), 0.35 ± 0.18 (skin), 0.07 ± 0.09 (heart), 0.03 ± 0.04 (brain), 0.03 ± 0.03 (muscle), and 0.21 ± 0.08 (blood). <sup>111</sup>In-DOTA-Re(Arg<sup>11</sup>)CCMSH appeared to exhibit faster whole-body clearance and significantly higher 24-h tumor radioactivity level than <sup>99m</sup>Tc-(Arg<sup>11</sup>)CCMSH.</p><p>In the pulmonary metastatic tumor model, the radioactivity levels (% ID/g) of <sup>111</sup>In-DOTA-Re(Arg<sup>11</sup>)CCMSH in the lung metastases (<i>n</i> = 4) were 9.10 ± 2.86 (2 h) and 7.75 ± 3.66 (4 h) (<a class="bibr" href="#CCMSH111In.EXTYLES.2" rid="CCMSH111In.EXTYLES.2">2</a>). The radioactivity levels (% ID/g) in the normal lung were 0.23 ± 0.05 (2 h) and 0.08 ± 0.03 (4 h). The lung metastases/normal lung ratios were 39.57 and 96.88 at 2 h and 4 h, respectively. The lung metastases/muscle ratios were 130.00 and 193.75 at 2 h and 4 h, respectively. In the imaging studies that fused SPECT images with images of computed tomography, the flank melanoma tumors were visualized clearly at 2 h. The pulmonary metastatic melanoma lesions were also clearly imaged at 2 h, and distinct metastatic focal deposits were visible.</p></div><div id="CCMSH111In.Other_NonPrimate_Mam"><h3>Other Non-Primate Mammals</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28%2899mTc-%20and%20111In-labeled%20alpha-melanocyte-stimulating%20hormone%20peptides%29%20AND%20%28dog%20OR%20rabbit%20OR%20pig%20OR%20sheep%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="CCMSH111In.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28%2899mTc-%20and%20111In-labeled%20alpha-melanocyte-stimulating%20hormone%20peptides%29%20OR%20%28radiolabeled-alpha-MSH%29%29%20AND%20%28primate%20NOT%20human%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div></div><div id="CCMSH111In.Human_Studies"><h2 id="_CCMSH111In_Human_Studies_">Human Studies</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28%2899mTc-%20and%20111In-labeled%20alpha-melanocyte-stimulating%20hormone%20peptides%29%20OR%20%28radiolabeled-alpha-MSH%29%29%20AND%20human" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="CCMSH111In.NIH_Support"><h2 id="_CCMSH111In_NIH_Support_">NIH Support</h2><p>NCI R41 A85106, P50-CA-130130</p></div><div id="CCMSH111In.references"><h2 id="_CCMSH111In_references_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.1">Cheng Z. , Chen J. , Miao Y. , Owen N.K. , Quinn T.P. , Jurisson S.S. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. <span><span class="ref-journal">J Med Chem. </span>2002;<span class="ref-vol">
|
|
<strong>45</strong>
|
|
</span>(14):3048–56.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12086490" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12086490</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.2">Miao Y. , Benwell K. , Quinn T.P. 99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. <span><span class="ref-journal">J Nucl Med. </span>2007;<span class="ref-vol">
|
|
<strong>48</strong>
|
|
</span>(1):73–80.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17204701" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17204701</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.3">Miao Y. , Hylarides M. , Fisher D.R. , Shelton T. , Moore H. , Wester D.W. , Fritzberg A.R. , Winkelmann C.T. , Hoffman T. , Quinn T.P. Melanoma therapy via peptide-targeted {alpha}-radiation. <span><span class="ref-journal">Clin Cancer Res. </span>2005;<span class="ref-vol">
|
|
<strong>11</strong>
|
|
</span>(15):5616–21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16061880" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16061880</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.4">Bohm M. , Luger T.A. , Tobin D.J. , Garcia-Borron J.C. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. <span><span class="ref-journal">J Invest Dermatol. </span>2006;<span class="ref-vol">
|
|
<strong>126</strong>
|
|
</span>(9):1966–75.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16912693" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16912693</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.5">Catania A. , Airaghi L. , Garofalo L. , Cutuli M. , Lipton J.M. The neuropeptide alpha-MSH in HIV infection and other disorders in humans. <span><span class="ref-journal">Ann N Y Acad Sci. </span>1998;<span class="ref-vol">
|
|
<strong>840</strong>
|
|
</span>:848–56.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9629310" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9629310</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.6">Dimitrakopoulou-Strauss A. , Strauss L.G. , Burger C. Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. <span><span class="ref-journal">J Nucl Med. </span>2001;<span class="ref-vol">
|
|
<strong>42</strong>
|
|
</span>(2):248–56.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11216523" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11216523</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.7">Weiner R.E. , Thakur M.L. Radiolabeled peptides in oncology: role in diagnosis and treatment. <span><span class="ref-journal">BioDrugs. </span>2005;<span class="ref-vol">
|
|
<strong>19</strong>
|
|
</span>(3):145–63.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15984900" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15984900</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.8">Tatro J.B. , Reichlin S. Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents. <span><span class="ref-journal">Endocrinology. </span>1987;<span class="ref-vol">
|
|
<strong>121</strong>
|
|
</span>(5):1900–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2822378" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2822378</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.9">Siegrist W. , Solca F. , Stutz S. , Giuffre L. , Carrel S. , Girard J. , Eberle A.N. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. <span><span class="ref-journal">Cancer Res. </span>1989;<span class="ref-vol">
|
|
<strong>49</strong>
|
|
</span>(22):6352–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2804981" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2804981</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.10">Chen J. , Cheng Z. , Hoffman T.J. , Jurisson S.S. , Quinn T.P. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. <span><span class="ref-journal">Cancer Res. </span>2000;<span class="ref-vol">
|
|
<strong>60</strong>
|
|
</span>(20):5649–58.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11059756" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11059756</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.11">Miao Y. , Whitener D. , Feng W. , Owen N.K. , Chen J. , Quinn T.P. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. <span><span class="ref-journal">Bioconjug Chem. </span>2003;<span class="ref-vol">
|
|
<strong>14</strong>
|
|
</span>(6):1177–84.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14624632" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14624632</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.12">Giblin M.F. , Wang N. , Hoffman T.J. , Jurisson S.S. , Quinn T.P. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1998;<span class="ref-vol">
|
|
<strong>95</strong>
|
|
</span>(22):12814–8.</span> [<a href="/pmc/articles/PMC23606/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC23606</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9788997" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9788997</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.13">Chen J. , Cheng Z. , Owen N.K. , Hoffman T.J. , Miao Y. , Jurisson S.S. , Quinn T.P. Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. <span><span class="ref-journal">J Nucl Med. </span>2001;<span class="ref-vol">
|
|
<strong>42</strong>
|
|
</span>(12):1847–55.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11752084" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11752084</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.14">Chen J. , Cheng Z. , Miao Y. , Jurisson S.S. , Quinn T.P. <span class="ref-title">Alpha-melanocyte-stimulating hormone peptide analogs labeled with technetium-99m and indium-111 for malignant melanoma targeting </span><span class="ref-journal">Cancer</span> 2002<strong>94</strong>Suppl4:1196–201. [<a href="https://pubmed.ncbi.nlm.nih.gov/11877745" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11877745</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.15">Eberle A.N. , Froidevaux S. Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium. <span><span class="ref-journal">J Mol Recognit. </span>2003;<span class="ref-vol">
|
|
<strong>16</strong>
|
|
</span>(5):248–54.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14523936" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14523936</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.16">Froidevaux S. , Calame-Christe M. , Tanner H. , Eberle A.N. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. <span><span class="ref-journal">J Nucl Med. </span>2005;<span class="ref-vol">
|
|
<strong>46</strong>
|
|
</span>(5):887–95.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15872364" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15872364</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.17">Miao Y. , Owen N.K. , Whitener D. , Gallazzi F. , Hoffman T.J. , Quinn T.P. In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. <span><span class="ref-journal">Int J Cancer. </span>2002;<span class="ref-vol">
|
|
<strong>101</strong>
|
|
</span>(5):480–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12216078" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12216078</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.18">Froidevaux S. , Calame-Christe M. , Schuhmacher J. , Tanner H. , Saffrich R. , Henze M. , Eberle A.N. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. <span><span class="ref-journal">J Nucl Med. </span>2004;<span class="ref-vol">
|
|
<strong>45</strong>
|
|
</span>(1):116–23.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14734683" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14734683</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="CCMSH111In.EXTYLES.19">Miao Y. , Hoffman T.J. , Quinn T.P. Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. <span><span class="ref-journal">Nucl Med Biol. </span>2005;<span class="ref-vol">
|
|
<strong>32</strong>
|
|
</span>(5):485–93.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15982579" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15982579</span></a>]</div></dd></dl></dl></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin"><div>This MICAD chapter is not included in the Open Access Subset, because it was authored / co-authored by one or more investigators who was not a member of the MICAD staff.</div></p></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK23602_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Kenneth T. Cheng</span>, PhD<div class="affiliation small">
|
|
National Center for Biotechnology Information, NLM, NIH, Bethesda, MD,
|
|
<span class="before-email-separator"></span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.mln.ibcn@dacim" class="oemail">vog.hin.mln.ibcn@dacim</a>
|
|
</div></div><div class="contrib half_rhythm"><span itemprop="author">Zhen Cheng</span>, PhD<div class="affiliation small">
|
|
Molecular Imaging Program, Department of Radiology and Bio-X Program, Stanford University, CA,
|
|
<span class="before-email-separator"></span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.drofnats@gnehz" class="oemail">ude.drofnats@gnehz</a>
|
|
</div></div><div class="contrib half_rhythm"><span itemprop="author">Thomas P. Quinn</span>, PhD<div class="affiliation small">
|
|
Department of Biochemistry, University of Missouri-Columbia, Columbia, MO, Corresponding Author,
|
|
<span class="before-email-separator"></span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.iruossim@tnniuq" class="oemail">ude.iruossim@tnniuq</a>
|
|
</div></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">September 1, 2007</span>; Last Update: <span itemprop="dateModified">December 17, 2007</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Cheng KT, Cheng Z, Quinn TP. 111In-DOTA-Re(Cys3,4,10,d-Phe7,Arg11)αMSH3-13. 2007 Sep 1 [Updated 2007 Dec 17]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/RM1-DOTA-111In/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/DPC11870In111/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobCCMSH111InT1"><div id="CCMSH111In.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK23602/table/CCMSH111In.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CCMSH111In.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>111</sup>In-DOTA-Re(Arg<sup>11</sup>)(Cys<sup>3,4,10</sup>,<span class="small-caps">d</span>-Phe<sup>7</sup>)-αMSH<sub>3-13</sub></td><td rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<div class="graphic"><img src="/books/NBK23602/bin/CCMSH111In.jpg" alt="Image CCMSH111In.jpg" /></div>
|
|
</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>111</sup>In-DOTA-Re(Arg<sup>11</sup>)CCMSH</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>111</sup>In-α-MSH, <sup>111</sup>In-labeled α-melanocyte–stimulating hormone peptides</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Peptide</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Melanocortin-1 (MC-1) receptor</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Peptide-receptor binding</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Single-photon emission computed tomography (SPECT) or gamma planar imaging</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>111</sup>In</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li></ul>
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Rodents
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>111</sup>In-DOTA- Re(Arg<sup>11</sup>)CCMSH.<br />Click on <a href="/entrez/viewer.fcgi?db=protein&val=27477129" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">protein</a>, <a href="/entrez/viewer.fcgi?db=nucleotide&val=27477128" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">nucleotide</a> (RefSeq), and <a href="/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=4157" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">gene</a> for more information about the melanocortin-1 receptor.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|